Literature DB >> 19741235

Mutation in TET2 in myeloid cancers.

Ayalew Tefferi, Ken-Hong Lim, Ross Levine.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19741235     DOI： 10.1056/NEJMc091348

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  22 in total

1.  Tet1 and 5-hydroxymethylation: a genome-wide view in mouse embryonic stem cells.

Authors:  Hao Wu; Yi Zhang
Journal:  Cell Cycle       Date:  2011-08-01       Impact factor: 4.534

2.  Harnessing Hematopoietic Stem Cell Low Intracellular Calcium Improves Their Maintenance In Vitro.

Authors:  Larry L Luchsinger; Alexandros Strikoudis; Nichole M Danzl; Erin C Bush; Michael O Finlayson; Prakash Satwani; Megan Sykes; Masayuki Yazawa; Hans-Willem Snoeck
Journal:  Cell Stem Cell       Date:  2019-06-06       Impact factor: 24.633

3.  Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event.

Authors:  M Jawhar; J Schwaab; S Schnittger; K Sotlar; H-P Horny; G Metzgeroth; N Müller; S Schneider; N Naumann; C Walz; T Haferlach; P Valent; W-K Hofmann; N C P Cross; A Fabarius; A Reiter
Journal:  Leukemia       Date:  2015-01-08       Impact factor: 11.528

4.  Antibiotic treatment ameliorates Ten-eleven translocation 2 (TET2) loss-of-function associated hematological malignancies.

Authors:  Hongxiang Zeng; Hailan He; Lei Guo; Jia Li; Minjung Lee; Wei Han; Anna G Guzman; Shengbing Zang; Yubin Zhou; Xiaotian Zhang; Margaret A Goodell; Katherine Y King; Deqiang Sun; Yun Huang
Journal:  Cancer Lett       Date:  2019-09-26       Impact factor: 8.679

5.  Aberrations identified by genomic arrays in normal karyotype CMML can be detected in 40% of patients, but do not add prognostic information to molecular mutations.

Authors:  C Vetro; C Haferlach; T Haferlach; M Zenger; N Nadarajah; W Kern; M Meggendorfer
Journal:  Leukemia       Date:  2016-05-25       Impact factor: 11.528

6.  DNMT3A Haploinsufficiency Transforms FLT3ITD Myeloproliferative Disease into a Rapid, Spontaneous, and Fully Penetrant Acute Myeloid Leukemia.

Authors:  Sara E Meyer; Tingting Qin; David E Muench; Kohei Masuda; Meenakshi Venkatasubramanian; Emily Orr; Lauren Suarez; Steven D Gore; Ruud Delwel; Elisabeth Paietta; Martin S Tallman; Hugo Fernandez; Ari Melnick; Michelle M Le Beau; Scott Kogan; Nathan Salomonis; Maria E Figueroa; H Leighton Grimes
Journal:  Cancer Discov       Date:  2016-03-25       Impact factor: 39.397

7.  TET2 plays an essential role in erythropoiesis by regulating lineage-specific genes via DNA oxidative demethylation in a zebrafish model.

Authors:  Liang Ge; Rui-peng Zhang; Feng Wan; Dong-yang Guo; Ping Wang; Li-xin Xiang; Jian-zhong Shao
Journal:  Mol Cell Biol       Date:  2014-01-06       Impact factor: 4.272

Review 8.  A chromatin perspective on metabolic and genotoxic impacts on hematopoietic stem and progenitor cells.

Authors:  Zhenhua Yang; Hao Jiang
Journal:  Cell Mol Life Sci       Date:  2020-04-21       Impact factor: 9.261

9.  Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis.

Authors:  Raajit Rampal; Fatima Al-Shahrour; Omar Abdel-Wahab; Jay P Patel; Jean-Philippe Brunel; Craig H Mermel; Adam J Bass; Jennifer Pretz; Jihae Ahn; Todd Hricik; Outi Kilpivaara; Martha Wadleigh; Lambert Busque; D Gary Gilliland; Todd R Golub; Benjamin L Ebert; Ross L Levine
Journal:  Blood       Date:  2014-04-16       Impact factor: 22.113

10.  Tet2 facilitates the derepression of myeloid target genes during CEBPα-induced transdifferentiation of pre-B cells.

Authors:  Eric M Kallin; Javier Rodríguez-Ubreva; Jesper Christensen; Luisa Cimmino; Iannis Aifantis; Kristian Helin; Esteban Ballestar; Thomas Graf
Journal:  Mol Cell       Date:  2012-09-13       Impact factor: 17.970
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.